112529-15-4 Pioglitazone hydrochloride

Superiority:

Product Name: Pioglitazone hydrochloride
Synonyms: (+-5-[[4-[2-(5-ETHYL-2-PYRIDINYL)ETHOXY] PHENYL]METHYL]-2 4-] THIAZOLIDINEDIONE H YDROCHLORIDE(PIOGLITAZONE HCL);Pioglitazone hydrochloride, 99%, receptor-gamma (PPARgamma) agonist;Pioglitazone hydrochloride, >=99%;thiazolidinedione hydrochloride;5-[4-[2-(5-Ethyl-2-pyridyl)ethoxy]benzyl]thiazolidine-2,4-dione hydrochloride;5-((4-(2-(5-ETHYL-2-PYRIDINYL)ETHOXY)PHENYL)METHYL)-2,4-THIAZOLIDINEDIONE, HCL;[5-[[4-[2-(5-ethyl-2-pyridinyl)ethoxy]phenyl]methyl]-2,4-] thiazolidinedione hydrochloride;ACTOS
CAS: 112529-15-4
MF: C19H21ClN2O3S
MW: 392.9
EINECS: 629-731-9
Product Categories: API;Cardiovascular Series;Active Pharmaceutical Ingredients;Antidiabetic;Diabetes;Heterocycles;Intermediates & Fine Chemicals;Pharmaceuticals;Sulfur & Selenium Compounds;API's;Pioglitazone;Inhibitor
Mol File: 112529-15-4.mol

Pioglitazone hydrochloride Chemical Properties
Melting point  193-194°C
RTECS  XJ5813440
storage temp.  Desiccate at RT
solubility  DMSO: ≥10mg/mL
form  powder
color  white to off-white
Water Solubility  Soluble in water (<1 mg/ml at 25°C), DMF, methanol, ethanol (4 mg/ml at 25°C), and DMSO (79 mg/ml at 25°C).
Merck  14,7452
InChIKey GHUUBYQTCDQWRA-UHFFFAOYSA-N
CAS DataBase Reference 112529-15-4(CAS DataBase Reference)
Safety Information
Hazard Codes  Xi
Risk Statements  36/38-36
Safety Statements  22-24/25-26
WGK Germany  3
HazardClass  IRRITANT
HS Code  29341000
MSDS Information
Pioglitazone hydrochloride Usage And Synthesis
Description Pioglitazone is a new orally active thiazolidinedione (TZD) launched in the US for the treatment of non-insulin dependent diabetes mellitus (NIDDM). It can be synthesized in 4 steps, the last one transforming an alphabromoester into thiazolidine with thiourea. As with other representatives in this class, it potently activates the nuclear receptor peroxisome proliferator-activated receptor gamma which is believed to be involved in the regulation of insulin resistance and adipogenesis. In several obese and obese diabetic animal models, treatment with Pioglitazone resulted in reductions in plasma glucose and serum lipids. In clinical studies, Pioglitazone at a once daily oral dose of 15-45 mg, as monotherapy or in combination with non-TZDs or insulin, was shown to significantly improve glycemic control in type-2 diabetes and demonstrated a beneficial effect on insulin resistance and other clinically relevant parameters as plasma levels of triglycerides or HDL-cholesterol. Pioglitazone is reported to be safe and well tolerated and is said to have a lower occurrence of hepatic toxicity as well as a low probability for drug interaction.
Chemical Properties Colourless Prisms
Originator Takeda (Japan)
Uses euglycemic agent
Uses Pioglitazone hydrochloride is a euglycemic agent,used as an antidiabetic.